Treatment Outcome and Prognostic factors of Glioblastoma Multiforme | ||||
| SECI Oncology Journal | ||||
| Article 3, Volume 12, Issue 4, October 2024, Page 344-352 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background and Aim: Background and aim: This is a retrospective study of Egyptian patients with glioblastoma multiforme who had undergone biopsy and or surgical resection and radiation to identify clinical, pathological, radiological and to asses treatment outcome (overall survival OS and progression free survival PFS). Patients and methods: two hundreds & ten patients with glioblastoma multiforme data was collected and recorded in a personal database from paper and electronic medical records and variables were analyzed. Results: The median overall survival time was 9 months, while the median time to progression was 6 months. Multivariate analysis revealed that ECOG PS, absence of adjuvant temozolamide, tumor site, were statistically significant independent predictors for overall survival OS and progression free survival PFS. Hazard ratios & confidence intervals of OS were 1.72 (1.16-2.56), 1.94 (1.41-2.67), 1.43 (1.05-1.94) respectively, while for PFS, Hazard ratios & confidence intervals were 2.1 (1.5-2.9), 1.4 (1.05-1.9), and 1.44 (0.98-2.13), respectively. Conclusion: Glioblastoma multiforme still an aggressive disease with short PFS and OS. Good performance status, TMZ chemotherapy and tumor location were significant prognostic factors. | ||||
| Keywords | ||||
| Glioblastoma multiforme; prognostic factors; overall survival; progression free survival | ||||
|
Supplementary Files
|
||||
|
Statistics Article View: 63 |
||||
